PreSENTIA hereditary cancer test panels can detect numerous inherited genetic changes (mutations) that could cause cancer in the future.
PreSENTIA offers an extensive portfolio of 19 hereditary cancer test panels. Each panel focuses on a set of genes that determine someone’s chances of developing a specific cancer in the future. The genetic changes in the genes that could cause cancer are inherited from parents to their children, and are present from birth. Knowing that a person carries one of these genetic mutations can help them take preventative measures and plan a more informed clinical management. As a result, early detection of cancer can be achieved – which increases the chances of successful treatment – or prevention.
WHAT IS CANCER?
Cancer is the rapid and uncontrollable growth of abnormal cells. It is the second leading cause of death, responsible for 1 out of 6 deaths globally. World Health Organization (WHO) recommends that cancer mortality can be significantly reduced by early detection and proper clinical management of cancers.
HOW DOES CANCER DEVELOP?
Cancer develops after certain genes that are responsible for keeping our body healthy undergo changes that cause them to become ‘faulty’. A cancer can be:
SPORADIC: Mutations in the genes causing cancer accumulate over time due to risk factors like tobacco, viruses (such as HPV), and environmental factors. These mutations cannot be inherited.
HEREDITARY: These mutations exist from birth. They run in families and can be passed down from parents to their children.
Inherited genetic mutations make up for 5-10% of all cancers.
WHAT SHOULD I ASK MY DOCTOR?
What are germline mutations?
Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.
What is a hereditary screening test?
A hereditary screening test checks if an individual has an inherited gene mutation in a gene with high cancer susceptibility.
If you or a family member were diagnosed with hereditary cancer, or a genetic change that is linked to cancer, there's a high chance other members of your family carry the genetic change as well. Each individual could be affected by cancer at different age, with wide range of severity, and by different cancer types.
WHO IS THIS TEST FOR?
Identifying the genetic change that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning, avoiding risk factors and informing family members of their risk.
According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have:
- Family members with cancer in the same side of the family
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
- Personal or family history of a hereditary cancer syndrome
Your healthcare provider will also take into account your medical family history, ethnicity and any physical findings present linked to cancer before recommending PreSENTIA to you.
* Data adapted from: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology and American College of Obstetricians and Gynecologists.
HOW DOES PreSENTIA HELP ME?
PreSENTIA panels test for numerous genetic changes that are responsible for causing hereditary cancers. If you want to know more about your cancer risks, or if you have been already diagnosed with cancer and you want to know whether your cancer is hereditary, PreSENTIA can help.
- Targeted cancer monitoring – recommended screening tests at key time intervals to detect cancer early, when treatment is more beneficial
- Prevention of cancer by prophylactic measures
- Actionable information for family members that might carry the same gene
- Improved classification of the disease for better clinical management
- Drug therapy (chemoprevention)
WHY CHOOSE THE PreSENTIA TEST?
- Assesses clinically important mutations
- Ability to select the best panel for you
- Reliable technology
- Short turn-around time
- Safe and easy to perform
WHAT ARE ‘HEREDITARY CANCER SYNDROMES’?
Hereditary cancer syndromes are also known as cancer predisposing syndromes, as patients with these syndromes have an elevated risk of developing specific cancers in the future. These conditions occur when genes with critical roles in keeping our body healthy are mutated, causing a variety of symptoms and potentially affecting the quality of life. They can be inherited from one generation to the other.
Hereditary cancer syndromes characteristics
- Multiple cancer types
- Repeated cancers
- Young age of cancer onset
If you have cancer in your family history and want to know about your own risk, PreSENTIA can help. By identifying the mutated genes that could cause hereditary cancer syndromes, PreSENTIA can provide information that could help in clinical management. If you have been diagnosed with cancer and have any of the above characteristics, you might also have a hereditary cancer syndrome. Identifying this can help reveal how and why your cancer was caused.
HOW ACCURATE IS IT?
TARGETED TECHNOLOGY
By focusing only on the genetic changes tested, PreSENTIA is accurate and precise.
HIGH READ DEPTH
PreSENTIA analyzes the locations of the genetic changes hundreds of times, making the test results more sensitive and reliable.
WHAT DOES IT TEST FOR?
HEREDITARY CANCER PANELS
-
BREAST & GYNECOLOGICAL
26
HEREDITARY BREAST/GYNECOLOGICAL CANCER PANEL
Description
Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for breast/gynaecological cancers are those that have:
- Several family members in the same side of the family with cancer
- Family members with early cancer onset
- Family members with rare cancer types
- A family member with multiple cancers
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- Personal history of previous malignancies
No of Genes Tested
26
No of related hereditary cancer syndromes
12
Genes Tested
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- DICER 1 syndrome (DICER1)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
- Polymerase proofreading associated syndrome (POLD1, POLE)
- PTEN hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4
-
BREAST / GYN GUIDELINES - BASED
19
HEREDITARY BREAST/GYNECOLOGICAL GUIDELINES-BASED CANCER PANEL
Description
Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- Several family members in the same side of the family with cancer
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
19
No of related hereditary cancer syndromes
9
Genes Tested
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11
Disorders associated with this panel:
- Ataxia telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Peutz-Jeghers syndrome (STK11)
- PTEN Hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D
-
BREAST
HIGH-RISK7
HEREDITARY BREAST HIGH-RISK CANCER PANEL
Description
Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- Several family members in the same side of the family with cancer
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
7
No of related hereditary cancer syndromes
5
Genes Tested
BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53
Disorders associated with this panel:
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Li-Fraumeni syndrome (TP53)
- Peutz-Jeughers syndrome (STK11)
- PTEN hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
PALB2
-
BRCA1 / BRCA2
2
HEREDITARY BRCA1 / BRCA2 CANCER PANEL
Description
Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers caused by mutations in the BRCA1/BRCA2 genes are those that have:
- Several family members with cancer in the same side of the family
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
2
No of related hereditary cancer syndromes
1
Genes Tested
BRCA1, BRCA2
Disorders associated with this panel:
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
-
COLORECTAL
17
HEREDITARY COLORECTAL CANCER PANEL
Description
Hereditary Colorectal cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- Personal history of previous malignancies
No of Genes Tested
17
No of related hereditary cancer syndromes
12
Genes Tested
APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
Disorders associated with this panel:
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- PTEN Hamartoma syndrome (PTEN)
- Peutz-Jeghers syndrome (STK11)
- Hereditary diffuse gastric syndrome (CDH1)
- MUTYH-associated polyposis syndrome (MUTYH)
- Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
- Polymerase Proofreading Associated syndrome (POLD1, POLE)
- Hereditary mixed polyposis syndrome (GREM1)
- Juvenile Polyposis syndrome (SMAD4, BMPR1A)
- Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)
-
COLORECTAL
HIGH-RISK10
HEREDITARY COLORECTAL HIGH-RISK CANCER PANEL
Description
Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
10
No of related hereditary cancer syndromes
6
Genes Tested
APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11
Disorders associated with this panel:
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
-
COLORECTAL
NON-POLYPOSIS5
HEREDITARY COLORECTAL NON-POLYPOSIS CANCER PANEL
Description
Hereditary Colorectal Non-Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
5
No of related hereditary cancer syndromes
2
Genes Tested
EPCAM, MLH1, MSH2, MSH6, PMS2
Disorders associated with this panel:
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
-
COLORECTAL POLYPOSIS SYNDROME
7
HEREDITARY COLORECTAL POLYPOSIS CANCER PANEL
Description
Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary polyposis colorectal cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
7
No of related hereditary cancer syndromes
5
Genes Tested
APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11
Disorders associated with this panel:
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
- Polymerase proofreading associated syndrome (POLD1, POLE)
-
MYELODYSPLASTIC SYNDROME/LEUKEMIA
24
HEREDITARY MYELODYSPLASTIC SYNDROME / LEUKEMIA CANCER PANEL
Description
Hereditary Myelodysplastic syndrome / Leukemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:
- Family history of a hereditary cancer syndrome associated with leukemia
- Personal history of a hereditary cancer syndrome associated with leukemia
- An identical twin who developed leukemia in the first year of life
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
24
No of related hereditary cancer syndromes
6
Genes Tested
ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
- Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
-
GASTRIC
14
HEREDITARY GASTRIC CANCER PANEL
Description
Hereditary Gastric cancer panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:
- Several family members in the same side of the family with gastric cancer
- Personal or family history of a hereditary cancer syndrome linked to gastric cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
14
No of related hereditary cancer syndromes
8
Genes Tested
APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53
Disorders associated with this panel:
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- Hereditary diffuse gastric syndrome (CDH1)
- Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
- Juvenile Polyposis syndrome (SMAD4, BMPR1A)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Peutz-Jeghers syndrome (STK11)
-
PROSTATE
15
HEREDITARY PROSTATE CANCER PANEL
Description
Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:
- Several first-degree family members with prostate cancer
- Family members diagnosed with prostate cancer at young age
- Family members diagnosed with other cancer types, including breast, ovarian and pancreatic
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
15
No of related hereditary cancer syndromes
6
Genes Tested
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
- PTEN hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
HOXB13, NBN, PALB2, RAD51D
-
PANCREATIC
17
HEREDITARY PANCREATIC CANCER PANEL
Description
Hereditary Pancreatic cancer panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:
- Several family members in the same side of the family with pancreatic cancer
- First-degree relative who developed pancreatic cancer before the age of 50
- Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
17
No of related hereditary cancer syndromes
10
Genes Tested
APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Multiple endocrine neoplasia type 1 (MEN1)
- Peutz-Jeghers syndrome (STK11)
-
RENAL
13
HEREDITARY RENAL CANCER PANEL
Description
Hereditary Renal cancer panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary renal cancers are those that have:
- Family members that have had renal cancer, especially at a young age
- Family members with renal cancer in both kidneys
- Family members diagnosed with a hereditary cancer syndrome associated with renal cancer
- Personal history of a hereditary cancer syndrome associated with renal cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
13
No of related hereditary cancer syndromes
7
Genes Tested
BAP1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL
Disorders associated with this panel:
- BAP1 mutation associated disease (BAP1)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- PTEN hamartoma syndrome (PTEN)
- Von-Hippel Lindau syndrome (VHL)
-
SKIN (XP-ASSOCIATED)
9
HEREDITARY SKIN (XP-ASSOCIATED) CANCER PANEL
Description
Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:
- Family or personal history of a hereditary cancer syndrome associated with skin cancers
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
9
No of related hereditary cancer syndromes
1
Genes Tested
DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC
Disorders associated with this panel:
- Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)
-
FAMILIAL MELANOMA
7
HEREDITARY FAMILIAL MELANOMA CANCER PANEL
Description
Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:
- At least two first-degree family member who have had metastatic melanoma
- At least one family member has had multiple melanomas
- Family or personal history of a hereditary cancer syndrome associated with melanoma
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
7
No of related hereditary cancer syndromes
5
Genes Tested
BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53
Disorders associated with this panel:
- BAP1 mutation associated disease (BAP1)
- Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
- Li-Fraumeni syndrome (TP53)
- PTEN hamartoma syndrome (PTEN)
- Retinoblastoma (RB1)
-
PARAGANGLIOMA / PHEOCHROMOCYTOMA
6
HEREDITARY PARAGANGLIOMA / PHEOCHROMOCYTOMA CANCER PANEL
Description
Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:
- Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
6
No of related hereditary cancer syndromes
3
Genes Tested
RET, SDHAF2, SDHB, SDHC, SDHD, VHL
Disorders associated with this panel:
- Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
- Multiple endocrine neoplasia type 2 (RET)
- Von-Hippel Lindau syndrome (VHL)
-
PARATHYROID
1
HEREDITARY PARATHYROID CANCER PANEL
Description
Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:
- At least two first-degree family member who have had parathyroid tumors
- A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
1
No of related hereditary cancer syndromes
1
Genes Tested
MEN1
Disorders associated with this panel:
- Multiple endocrine neoplasia type 1 (MEN1)
-
THYROID
1
HEREDITARY THYROID CANCER PANEL
Description
Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:
- At least one first-degree family member who has had thyroid cancer
- A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
1
No of related hereditary cancer syndromes
1
Genes Tested
RET
Disorders associated with this panel:
- Multiple endocrine neoplasia type 2 (RET)
-
PAN-CANCER
62
HEREDITARY PAN-CANCER PANEL
Description
Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- Several family members in the same side of the family with cancer
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- Family members with an unusual type of cancer (breast cancer in a male)
- Personal or family history of a hereditary cancer syndrome
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
62
No of related hereditary cancer syndromes
24
Genes Tested
APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- BAP1 mutation associated disease (BAP1)
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- DICER 1 syndrome (DICER1)
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Hereditary mixed polyposis syndrome (GREM1)
- Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
- Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Multiple endocrine neoplasia type 1 (MEN1)
- Multiple endocrine neoplasia type 2 (RET)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
- Polymerase proofreading associated syndrome (POLD1, POLE)
- PTEN hamartoma syndrome (PTEN)
- Retinoblastoma (RB1)
- Von-Hippel Lindau syndrome (VHL)
- Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D
-
Hereditary Cancer Syndromes
Cancer Predisposing Syndromes & Associated Genes Associated Cancers Li-Fraumeni syndrome
TP53Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain, Lung, Leukemia Li-Fraumeni syndrome 2
CHEK2Breast, Sarcoma, Brain Hereditary breast and ovarian cancer syndrome
BRCA1, BRCA2Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus Familial adenomatous polyposis/Attenuated familial adenomatous polyposis syndrome
APCGastric, Pancreatic, Colorectal, Osteomas, Small Bowel MUTYH-associated polyposis syndrome
MUTYHColorectal Lynch syndrome
MLH1, MSH2, MSH6, PMS2, EPCAMColorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal PTEN hamartoma syndrome
PTENBreast, Endometrial, Colorectal, Melanoma, Renal Peutz-Jeghers syndrome
STK11Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic Juvenile polyposis syndrome
SMAD4, BMPR1AColorectal, Gastric, Pancreatic Fanconi anemia syndrome
FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51CLeukemia, Tumors of the head & neck, Gastrointestinal Von-Hippel Lindau syndrome
VHLRenal, Paragangliomas, Pheochromocytomas Retinoblastoma
RB1Eye, Bone, Uveal Melanoma Xeroderma pigmentosum syndrome
DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA,XPCNon-Melanoma & Melanoma Hereditary melanoma-pancreatic cancer syndrome
CDKN2A, CDK4Melanoma, Pancreatic Hereditary diffuse gastric syndrome
CDH1Gastric & Breast DICER 1 syndrome
DICER1Lung, Renal, Ovarian, Thyroid Polymerase Proofreading Associated syndrome
POLD1, POLEColorectal & Endometrial Multiple Endocrine Neoplasia (MEN) syndrome type 1
MEN1Parathyroid & Pancreatic Multiple Endocrine Neoplasia (MEN) syndrome type 2
RETThyroid & Pheochromocytoma BAP1 Mutation associated disease
BAP1Skin, Eye, Renal, Mesothelioma Ataxia-telangiectasia syndrome
ATMLeukemia & Lymphoma Hereditary-mixed polyposis syndrome Renal, Paragangliomas, Pheochromocytomas
GREM1Colorectal Constitutional mismatch repair syndrome
MSH2, MSH6, MLH1, PMS2Hematologic malignancies, Brain, Gastrointestinal, Colorectal Hereditary Paraganglioma – Pheochromocytoma syndrome
SDHAF2, SDHB, SDHC, SDHDRenal, Thyroid, Paragangliomas, Pheochromocytomas
HOW CAN I TAKE PreSENTIA?
-
CONSULT WITH YOUR HEALTHCARE PROVIDER ON WHICH PANEL IS IDEAL FOR YOU
-
YOUR DOCTOR WILL COLLECT A BUCCAL SWAB SAMPLE FROM YOU
THE SAMPLE WILL BE SENT TO OUR LABORATORY
THE SAMPLE WILL BE ANALYZED IN OUR LABORATORY
RESULTS WILL BE SENT TO YOUR HEALTHCARE PROVIDER WITHIN 2-3 WEEKS
FAQ
-
What are mutations?
A mutation is a change that happens in the DNA that could possibly affect the health of an individual.
-
What is genetic testing?
Genetic testing identifies changes in the DNA.
-
What is cancer susceptibility and cancer predisposition?
Cancer susceptibility, or predisposition, is the likelihood of being affected by cancer in the future. This depends on an individual’s DNA. There are certain inherited, genetic changes that raise someone’s risk of developing cancer in the future. This is because these changes happen in genes that are responsible for protecting the body from disease, and when they are affected, their protective role halts.
-
What are germline mutations?
Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. Germline mutations are different from somatic mutations, which occur when a genetic change happens in the DNA due to exposure to risk factors – after a person is born. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.
-
What is hereditary screening?
A hereditary screening test checks if an individual has an inherited, genetic change in a gene with high cancer susceptibility from birth. Identifying the mutation that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning and avoiding risk factors.
-
How do I decide what is the best panel for me?
Your healthcare provider will recommend the best panel for you after considering the types of cancers that have affected your family members, any genetic changes that have already been diagnosed in one of your family members, and any symptoms exhibited. Consult with your healthcare provider on which panel is ideal.
NIPD Genetics - Privacy Policy
General Statement
This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.
If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.
NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.
Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.
You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus
NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com
This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:
- Type of personal information NIPD Genetics may collect through its Sites
- The ways by which NIPD Genetics collects, uses or shares such information
- Steps NIPD Genetics takes to protect its sites’ users personal information
- Your rights pertaining to your personal information, as explained in this Privacy Policy
NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.
This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.
We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com
Type of personal information NIPD Genetics may collect through its Sites
Information Collection And Use
We collect several different types of information for various purposes to provide and improve our Sites and services to you.
Personal Data
While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:
- Email address
- First name and last name
- Profession
- Phone number
- Address, State, Province, ZIP/Postal code, City
- IP address
If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.
Cookies and Usage Data
Usage Data
We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
Tracking & Cookies Data
We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.
Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.
Examples of Cookies we use:
Session Cookies. We use Session Cookies to operate our Sites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the Sites
Keyword cookies. To understand how visitors discover the Sites.
Use of Data
www.nipd.com uses the collected data for various purposes:
- To provide and maintain the Sites
- To notify you about changes to our Sites
- To allow you to participate in interactive features of our Sites when you choose to do so
- To provide customer care and support
- To provide analysis or valuable information so that we can improve the Sites
- To monitor the usage of the Sites
- To detect, prevent and address technical issues
Transfer of Data
Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.
www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.
Disclosure of Data
NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.
NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:
- To comply with a legal obligation
- To protect and defend the rights or property of www.nipd.com
- To prevent or investigate possible wrongdoing in connection with the Sites
- To protect the personal safety of users of the Sites or the public
- To protect against legal liability
Security of Data
The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.
Service Providers
We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
Analytics
We may use third-party Service Providers to monitor and analyze the use of our Sites.
Google Analytics
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.
For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page
Access to your personal data, correction, deletion, and Opting Out
You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com
Links to Other Sites
Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
Children's Privacy
Our Service does not address anyone under the age of 18 ("Children").
We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.
Changes to This Privacy Policy
We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.
We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.
You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.